Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: A perspective for adjuvant immunotherapy post-bone marrow transplantation

Bone Marrow Transplantation

Volumn 23, Issue 11, 1999, Pages 1153-1159

  Ibisch, C ^a   Gallot, G ^a   Vivien, R ^a   Diez, E ^a   Jotereau, F ^a   Garand, R ^b   Vie H ^a,b  

^a INSERM   (France)

^b INSTITUT DE BIOLOGIE   (France)

Author keywords

BMT; CTL; GVL; HLA DP; Immunotherapy

Indexed keywords

HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; B CELL LEUKEMIA; BLAST CELL; BONE MARROW TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FLUORESCENCE; GENETIC TRANSFECTION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKEMIA CELL; LYMPHOCYTE CLONE; PRIORITY JOURNAL;

EID: 0032972437     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701768     Document Type: Article

References (26)

1. Apperley J, Mauro FR, Goldman J et al. Bone marrow transplantation for chronic myelogenous leukemia in first chronic phase: importance of graft-versus-leukemia effect. Br J Haematol 1988; 69: 239-246.
2. Weiden PL, Sullivan K, Flournoy N et al. The Seattle marrow transplant team: antileukemic effect of chronci graft versus host disease. Contribution to improved survival after allogenic marrow transplantation. New Engl J Med 1981; 304: 1529-1533.
3. Horowitz MM, Gale PR, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
4. Sullivan KM, Storb R, Buckner CD et al. Graft versus host as adoptive immunotherapy in patients with advanced hematological neoplasms. New Engl J Med 1989; 320: 828-834.
5. Verdonck LF, Dekker AW, de Gast GC et al. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 1994; 83: 3090-3096.
6. Verdonck LF, de Gast GC, van Heugten HG, Decker AW. A fixed low number of T cells in HLA-identical allogeneic bone marrow transplantation. Blood 1990; 75: 776-780.
7. Kolb HJ, Mittermüller J, Clemm C et al. Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant recipients. Blood 1990; 76: 2462-2465.
8. Giralt SA, Champlin RE. Leukemia relapse after allogenic bone marrow transplantation: a review. Blood 1994; 84: 3603-3612.
9. Helg C, Roux P, Beris P et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993; 12: 125-129.
10. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogenic bone marrow transplantation: the case of giving donor leukocyte transfusion before the onset of hematologic disease. Blood 1994; 83: 3377-3383.
11. Bär BMAM, Schattenberg A, Mensink EJBM et al. Donor leukocyte infusion for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-519.
12. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogenic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
13. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus leukemia effect of donor lymphocyte transfusion in marrow graft patients. Blood 1995; 86: 2041-2050.
14. Tiberghien P, Reynolds CW, Keller J et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation. Blood 1994; 84: 1333-1341.
15. Petersdorf EF, Smith AG, Mickelson EM et al. The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. Blood 1993; 81: 1923-1932.
16. Moreau P, Cesbron A. HLA-DP and allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 13: 675-681.
17. Gaschet J, Mahe B, Milpied N et al. Specificity of T cells invading the skin during acute graft versus host disease after semi-allogeneic bone marrow transplantation. J Clin Invest 1993; 91: 12-20.
18. Gaschet J, Trevino MA, Cherel M et al. HLA-target anitgen and TCR diversity of activated T cells invading the skin during acute graft-vs-host disease. Blood 1996; 87: 2345-2353.
19. Gaschet J, Lim A, Liem L et al. Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1* 0501 mismatch. J Clin Invest 1996; 98: 100-107.
20. Gashet J, Gallot G, Ibisch C et al. Acute graft-versus-host disease after bone marrow transplantation with a single HLA-DPB1* 1001 mismatch: involvement of different TCRBV subsets. Bone Marrow Transplant 1998; 22: 385-392.
21. Gallot G, Hallet MM, Gaschet J et al. Human HLA-specific T cell clones with stable expression of a suicide gene: a possible tool to drive and control a graft-versus-host-graft-versus-leukemia reaction? Blood 1996; 88: 1098-1103.
22. Gervois N, Guilloux Y, Diez E, Jotereau F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 1996; 183: 2403-2407.
23. David-Ameline J, Lim A, Davodeau F et al. Selection of T cells reactive against autologous B lymphoblastoid cells during chronic rheumatoid arthritis. J Immunol 1996; 157: 4697-4706.
24. Sayed MH, Watschinger B, Carpenter BC. Mechanism of T cell recognition of alloantigens. The role of peptides. Transplantation 1994; 57: 1295-1302.
25. Tötterman TH, Gidlund M, Nilsson K, Wigzell H. Natural killer (NK) sensitivity of phorbol ester-differentiated tumour cells correlates with disease activity in chronic B-lymphocytis leukemia. Br J Haematol 1982; 52: 563-570.
26. Foa R, Fierro MT, Raspadori D et al. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemia cells to allogeneic and autologous LAK effectors. Blood 1990; 76: 1349-1355.